ASH China Voice | Professor Li Zhihui: A New Paradigm for Donor Selection and Transplant Strategies Driven by Hereditary Predisposition Genes

ASH China Voice | Professor Li Zhihui: A New Paradigm for Donor Selection and Transplant Strategies Driven by Hereditary Predisposition Genes

2025.12.22
In recent years, with the rapid development of precision genomics, hereditary predisposition genes have gained increasing attention for their clinical value in the diagnosis and treatment of hematologic malignancies. At the 67th Annual Meeting of the American Society of Hematology (ASH), a study led by Professor Li Zhihui from Beijing Gaobo Boren Hospital was selected for oral presentation, systematically evaluating the impact of hereditary predisposition genes on outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and donor selection. Hematology Frontier invited Professor Li for an in-depth interpretation of this study and its implications for clinical practice.
ASH Expert Insights | Professor Jun Ma: Transforming FLT3-ITD AML Treatment from Dynamic Management and Optimized Maintenance to Targeted Breakthrough

ASH Expert Insights | Professor Jun Ma: Transforming FLT3-ITD AML Treatment from Dynamic Management and Optimized Maintenance to Targeted Breakthrough

2025.12.22
At this year’s American Society of Hematology (ASH) Annual Meeting, advances in FLT3-ITD acute myeloid leukemia (AML) delivered important clinical insights. From evolving treatment paradigms to optimized maintenance strategies and breakthroughs in targeted therapy, these studies consistently centered on precision medicine, driving care toward greater efficiency and individualization. On site at ASH, Hematology Frontier invited Professor Jun Ma from the Harbin Institute of Hematology and Oncology to interpret key developments in dynamic management, maintenance therapy, and targeted drug application in FLT3-ITD AML, with the aim of informing clinical decision-making.